A little over two years ago, Acrux raised $22.5 million in a placement at $1.60.
What's changed since then?
Evamist sales have definitely been a disappointment. It's hard not to think KV's travails have prevented a decent marketing and sales campaign, though, so I don't think this is an indictment of Acrux's core technology.
The loss of the Organon partnership has also been a blow.
On the plus side, Acrux has obtained the data necessary for Ellavie registration effectively for nothing. And the three small agreements for South Africa, South Korea, and Switzerland bode well for finding an EU partner.
And the Axiron trials have been completed. This will be a bigger plus once we get confirmation they were successful.
The first Eli Lilly product being submitted for registration is a plus. The NSAIDs program is another. And pushing Vivus to progress with Testosterone MDTS might produce something.
All up I think Acrux is still a long-term buy, for the sheer width, length and speed of its product pipeline.
ACR Price at posting:
$1.57 Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)